Debbie Doppelt, a 60-year-old jeweler with an unusual form of lung cancer that afflicts mostly nonsmokers like her. The Food and Drug Administration hadn't yet approved sunvozertinib, a drug developed in China that targets the mutation driving Doppelt's tumors.
Sunvozertinib, made by Shanghai-based Dizal Pharmaceutical, isn't the only treatment drawing patients to China. Americans, Europeans and others are trekking there to enter clinical trials for CAR-T therapy, an area in which China has become a world leader.
